1
|
Patra SA, Sahu G, Das S, Dinda R. Recent Advances in Mitochondria-Localized Luminescent Ruthenium(II) Metallodrugs as Anticancer Agents. ChemMedChem 2023; 18:e202300397. [PMID: 37772783 DOI: 10.1002/cmdc.202300397] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Revised: 09/27/2023] [Accepted: 09/28/2023] [Indexed: 09/30/2023]
Abstract
Presently, the most effective way to transport drugs specifically to mitochondria inside the cells is of pharmacophoric interest, as mitochondria are recognized as one of the most important targets for new drug design in cancer diagnosis. To date, there are many reviews covering the photophysical, photochemical, and anticancer properties of ruthenium(II) based metallodrugs owing to their high interest in biological applications. There are, however, no reviews specifically covering the mitochondria-localized luminescent Ru(II) complexes and their subsequent mitochondria-mediated anticancer activities. Therefore, this review describes the physicochemical basis for the mitochondrial accumulation of ruthenium complexes, their synthetic strategies to localize and monitor the mitochondria in living cells, and their related underlying anticancer results. Finally, we review the related areas from previous works describing the mitochondria-localized ruthenium complexes for the treatment of cancer-related diseases. Along with this, we also deliberate the perspectives and future directions for emerging more bifunctional Ru(II) complexes that can target, image, and kill tumors more efficiently in comparison with the existing mitochondria-targeted cancer therapeutics.
Collapse
Affiliation(s)
- Sushree Aradhana Patra
- Department of Chemistry, National Institute of Technology, Rourkela, 769008, Odisha, India
| | - Gurunath Sahu
- Department of Chemistry, National Institute of Technology, Rourkela, 769008, Odisha, India
| | - Sanchita Das
- Department of Chemistry, National Institute of Technology, Rourkela, 769008, Odisha, India
| | - Rupam Dinda
- Department of Chemistry, National Institute of Technology, Rourkela, 769008, Odisha, India
| |
Collapse
|
2
|
López-Hernández JE, Contel M. Promising heterometallic compounds as anticancer agents: Recent studies in vivo. Curr Opin Chem Biol 2023; 72:102250. [PMID: 36566618 PMCID: PMC10880551 DOI: 10.1016/j.cbpa.2022.102250] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2022] [Revised: 11/21/2022] [Accepted: 11/23/2022] [Indexed: 12/24/2022]
Abstract
Over the past decade, interest on multitarget anticancer drugs -including heterometallic compounds-has increased considerably. Heterometallic species display improved efficacy and physicochemical properties compared to the individual metallic fragments for a variety of metal pair combinations. By 2018, several compounds had emerged as promising candidates against cisplatin resistant cancers. Here, we summarize research contributions to this topic over the past four years (July 2018-July 2022). In particular, we highlight five articles reporting on the in vivo activity and preliminary mechanisms of action for five groups of compounds. From this selection, we further feature two families of compounds based on Pt(IV)-Gd(III) and Ti(IV)-Au(I) metal combinations, given their potential for clinical translation.
Collapse
Affiliation(s)
- Javier E López-Hernández
- Department of Chemistry, The City University of New York, 2900 Bedford Avenue, Brooklyn, NY, 11210, USA; Brooklyn College Cancer Center BCCC-CURE, Brooklyn College, The City University of New York, 2900 Bedford Avenue, Brooklyn, NY, 11210, USA; Biochemistry, The Graduate Center, The City University of New York, 365 5th Avenue, New York, 11006, USA
| | - Maria Contel
- Department of Chemistry, The City University of New York, 2900 Bedford Avenue, Brooklyn, NY, 11210, USA; Brooklyn College Cancer Center BCCC-CURE, Brooklyn College, The City University of New York, 2900 Bedford Avenue, Brooklyn, NY, 11210, USA; Biochemistry, The Graduate Center, The City University of New York, 365 5th Avenue, New York, 11006, USA; Chemistry, The Graduate Center, The City University of New York, 365 5th Avenue, New York, 11006, USA; Biology PhD Programs, The Graduate Center, The City University of New York, 365 5th Avenue, New York, 11006, USA.
| |
Collapse
|
3
|
Milutinović MM, Caković AZ, Ćoćić D, Rais E, Schoch R, Marković BS, Arsenijević N, Volarević V, Jovanović-Stević S, Bogojeski JV, Wilhelm R. Unique enantiopure camphor-based neutral arene–ruthenium(II) complexes: DNA/BSA binding, kinetic and cytotoxic studies. J COORD CHEM 2022. [DOI: 10.1080/00958972.2022.2106562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Affiliation(s)
| | | | - Dušan Ćoćić
- Faculty of Science, University of Kragujevac, Kragujevac, Serbia
| | - Eduard Rais
- Department of Chemistry, University of Paderborn, Paderborn, Germany
| | - Roland Schoch
- Department of Chemistry, University of Paderborn, Paderborn, Germany
| | - Bojana Simović Marković
- Department of Microbiology and Immunology, Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
| | - Nebojša Arsenijević
- Department of Microbiology and Immunology, Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
| | - Vladislav Volarević
- Department of Microbiology and Immunology, Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
| | | | | | - René Wilhelm
- Institute of Organic Chemistry, Clausthal University of Technology, Clausthal-Zellerfeld, Germany
| |
Collapse
|
4
|
Wang J, Zhang Y, Li Y, Li E, Ye W, Pan J. Dinuclear Organoruthenium Complex for Mitochondria-Targeted Near-Infrared Imaging and Anticancer Therapy to Overcome Platinum Resistance. Inorg Chem 2022; 61:8267-8282. [PMID: 35584546 DOI: 10.1021/acs.inorgchem.2c00714] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
New mononuclear and dinuclear Ru(II) coordination compounds with the 2,7-bisbenzoimidazolyl-naphthyridine ligand have been synthesized and characterized by UV-vis, NMR, and MALDI-TOF. The molecular structures for Ru(II) compounds were determined by single-crystal X-ray diffraction. With the expansion of ligand π-conjugation and the increase in the complexed Ru number, the maximum emission wavelength red-shifted from 696 to 786 nm. The binding mode between complexes and DNA was predicted by molecular docking, which is intercalations and π-π stacking interactions with the surrounding bases. The intercalation mode of DNA binding was then determined by DNA titration and ethidium bromide (EB) displacement experiments. The antigrowth effects of complexes RuY, RuY1, and RuY2 were tested in HaCat (normal cells), HeLa (cervical cancer), A549 (lung cancer), and A549/DDP (cisplatin-resistant lung cancer) through the MTT assay. The dinuclear complex RuY2 was superior to mononuclear complexes and cisplatin in the cisplatin-resistant cell line. Confocal imaging proved that the subcellular localization of Ru(II) complexes was mitochondria; moreover, apoptosis was detected by flow cytometry. All three complexes showed a dose-dependent manner in all four cell lines. All Ru(II) complexes were found to have reactive oxygen species (ROS). The finding indicated that these Ru(II) complexes caused cell death by both DNA disruption and ROS. This study helps to explore the potential of the polynuclear Ru(II) complexes for the combination of NIR imaging and Pt-resistant cancer therapy.
Collapse
Affiliation(s)
- Jiaoyang Wang
- Key Laboratory for the Synthesis and Application of Organic Functional Molecules, College of Chemistry and Chemical Engineering, Hubei University, Wuhan 430062, P. R. China
| | - Yufei Zhang
- Key Laboratory for the Synthesis and Application of Organic Functional Molecules, College of Chemistry and Chemical Engineering, Hubei University, Wuhan 430062, P. R. China
| | - Yifan Li
- Key Laboratory for the Synthesis and Application of Organic Functional Molecules, College of Chemistry and Chemical Engineering, Hubei University, Wuhan 430062, P. R. China
| | - Enbo Li
- Key Laboratory for the Synthesis and Application of Organic Functional Molecules, College of Chemistry and Chemical Engineering, Hubei University, Wuhan 430062, P. R. China
| | - Wenjing Ye
- Key Laboratory for the Synthesis and Application of Organic Functional Molecules, College of Chemistry and Chemical Engineering, Hubei University, Wuhan 430062, P. R. China.,National & Local Joint Engineering Research Center of High-Throughput Drug Screening Technology, Hubei University, Wuhan 430062, P. R. China
| | - Jie Pan
- Key Laboratory for the Synthesis and Application of Organic Functional Molecules, College of Chemistry and Chemical Engineering, Hubei University, Wuhan 430062, P. R. China
| |
Collapse
|
5
|
Remarkably flexible 2,2′:6′,2″-terpyridines and their group 8–10 transition metal complexes – Chemistry and applications. Coord Chem Rev 2022. [DOI: 10.1016/j.ccr.2022.214426] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
6
|
NOVEL FERROCENYLBISPHOSPHONATE HYBRID COMPOUNDS: SYNTHESIS, CHARACTERIZATION AND POTENT ACTIVITY AGAINST CANCER CELL LINES. Bioorg Med Chem 2022; 58:116652. [DOI: 10.1016/j.bmc.2022.116652] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2021] [Revised: 12/29/2021] [Accepted: 01/28/2022] [Indexed: 11/19/2022]
|
7
|
Das U, Kar B, Pete S, Paira P. Ru(ii), Ir(iii), Re(i) and Rh(iii) based complexes as next generation anticancer metallopharmaceuticals. Dalton Trans 2021; 50:11259-11290. [PMID: 34342316 DOI: 10.1039/d1dt01326b] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Several anticancer drugs such as cisplatin, and its analogues, epirubicin, and doxorubicin are well known for their anticancer activity but the therapeutic value of these drugs comes with certain side effects and they cannot distinguish between normal and cancer cells. Thus, a major challenge for researchers around the world is to develop an anticancer drug with the least toxicity and more target specificity. With the successful reporting of NAMI-A and KP1019, a new path has emerged in the anticancer field. Recently, several Ru(ii) complexes have been reported for their anticancer activity due to their enhanced cellular uptake and selectivity towards cancer cells. Apart from the Ru(ii) complexes, a large amount of research has been carried out with Ir(iii), Re(i), and Rh(iii) based complexes, which exhibited promising anticancer activity. The present review reports various Ru(ii), Ir(iii), Re(i), and Rh(iii) based complexes for their anticancer activity based on their cytotoxicity profiles, biological targets and mechanism of action.
Collapse
Affiliation(s)
- Utpal Das
- Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore-632014, Tamilnadu, India.
| | | | | | | |
Collapse
|
8
|
Lazić D, Scheurer A, Ćoćić D, Milovanović J, Arsenijević A, Stojanović B, Arsenijević N, Milovanović M, Rilak Simović A. A new bis-pyrazolylpyridine ruthenium(III) complex as a potential anticancer drug: in vitro and in vivo activity in murine colon cancer. Dalton Trans 2021; 50:7686-7704. [PMID: 33982702 DOI: 10.1039/d1dt00185j] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
We synthesized and characterized the ruthenium(iii) pincer-type complex [RuCl3(H2Lt-Bu] (H2Lt-Bu = 2,6-bis(5-tert-butyl-1H-pyrazol-3-yl)pyridine, 1) by elemental analysis, IR and UV-Vis spectroscopy, and the mass spectrometry (MS) method ESI Q-TOF. For comparison reasons, we also studied ruthenium(iii) terpyridine complexes of the general formula [Ru(N-N-N)Cl3], where N-N-N = 4'-chloro-terpyridine (Cl-tpy; 2) or 4'-chlorophenyl-terpyridine (Cl-Ph-tpy; 3). A kinetic study of the substitution reactions of 1-3 with biomolecules showed that the rate constants depend on the properties of the spectator ligand and the nature of the entering nucleophile. The DNA/HSA binding study showed that in comparison to complex 1 (bis-pyrazolylpyridine), the other two (2 and 3) terpyridine complexes had a slightly better binding affinity to calf thymus DNA (CT DNA), while in the case of human serum albumin (HSA), complex 1 exhibited the strongest quenching ability. We demonstrated that 1 possesses significant in vitro cytotoxic activity against mouse colon carcinoma CT26 cells and in vivo antitumor activity in murine heterotopic colon carcinoma. Complex 1 induced G0/G1 cell cycle arrest and apoptotic death in CT26 cells. Additionally, 1 showed antiproliferative activity, as evaluated by the detection of the expression levels of the Ki67 protein. Furthermore, the in vivo results showed that 1 reduced primary tumour growth and the number and growth of lung and liver metastases, significantly prolonging the treated mice's survival rate. This study highlighted that 1 does not show hepato- and nephrotoxicity. Our data demonstrated the considerable antitumor activity of the ruthenium(iii) pincer complex against CT26 tumour cells and implicated further investigations of its role as a potential chemotherapeutic agent for colon carcinoma.
Collapse
Affiliation(s)
- Dejan Lazić
- Department of Surgery, Faculty of Medical Sciences, University of Kraujevac, Svetozara Markovića 69, 34000 Kragujevac, Serbia
| | - Andreas Scheurer
- Inorganic Chemistry, Department of Chemistry and Pharmacy, University of Erlangen-Nürnberg, Erlangen, Germany
| | - Dušan Ćoćić
- University of Kragujevac, Faculty of Science, Radoja Domanovića 12, P. O. Box 60, 34000 Kragujevac, Serbia
| | - Jelena Milovanović
- Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia. and Department of Histology, Faculty of Medical Sciences, University of Kragujevac, Serbia
| | - Aleksandar Arsenijević
- Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
| | - Bojana Stojanović
- Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia. and Department of Pathophysiology, Faculty of Medical Sciences, University of Kragujevac, Serbia
| | - Nebojša Arsenijević
- Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
| | - Marija Milovanović
- Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
| | - Ana Rilak Simović
- University of Kragujevac, Institute for Information Technologies Kragujevac, Department of Natural Sciences, Jovana Cvijića bb, 34000 Kragujevac, Serbia.
| |
Collapse
|
9
|
Fan YR, Wang BJ, Jia DG, Yang XB, Huang Y. Synthesis, electrochemistry, DNA binding and in vitro cytotoxic activity of tripodal ferrocenyl bis-naphthalimide derivatives. J Inorg Biochem 2021; 219:111425. [PMID: 33831713 DOI: 10.1016/j.jinorgbio.2021.111425] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2020] [Revised: 03/03/2021] [Accepted: 03/10/2021] [Indexed: 01/16/2023]
Abstract
A series of tripodal ferrocenyl bis-naphthalimide derivatives were synthesized and characterized. All of the bis-naphthalimide derivatives exhibited good DNA binding ability which was confirmed by ethidium bromide (EB) displacement experiment and ultraviolet (UV)-visible absorption titration. And the binding mode of these compounds was proved to be a hybrid binding mode by experiments. The cytotoxicity of synthesized compounds against 4 different human cancer cell lines (EC109, BGC823, SGC7901 and HEPG2) was evaluated by thiazolyl blue tetrazolium bromide (MTT) assay. All of the bis-naphthalimide derivatives exhibited good anticancer activity than the positive control drug (amonafide), which was due to the promotion of reactive oxygen species (ROS) level in test cancer cells by the reversible one-electron redox process of ferrocenyl bis-naphthalimide derivatives. Although there was no obvious relationship between the binding constants and the chain length, the structure cytotoxicity relationship revealed that the linker of n = 3, m = 1 was the best choice for the tested tripodol bis-naphthalimide derivatives. SYNOPSIS: A series of tripodal ferrocenyl bis-naphthalimide derivatives were synthesized to study the DNA binding ability and the cytotoxicity induced by reactive oxygen species. All of the compounds exhibited good DNA binding ability. And the structure cytotoxicity relationship revealed that the structure of 5h was the best choice.
Collapse
Affiliation(s)
- Yan-Ru Fan
- Key Laboratory of Hui Ethnic Medicine Modernization, Ministry of Education, Ningxia Engineering and Technology Research Center of Characteristic Chinese Medicine Modernization, College of Pharmacy, Ningxia Medical University, Yinchuan 750004, PR China
| | - Bo-Jin Wang
- Key Laboratory of Hui Ethnic Medicine Modernization, Ministry of Education, Ningxia Engineering and Technology Research Center of Characteristic Chinese Medicine Modernization, College of Pharmacy, Ningxia Medical University, Yinchuan 750004, PR China
| | - Deng-Guo Jia
- Key Laboratory of Hui Ethnic Medicine Modernization, Ministry of Education, Ningxia Engineering and Technology Research Center of Characteristic Chinese Medicine Modernization, College of Pharmacy, Ningxia Medical University, Yinchuan 750004, PR China
| | - Xin-Bin Yang
- Southwest University, Rongchang Campus, Chongqing 402460, PR China
| | - Yu Huang
- Key Laboratory of Hui Ethnic Medicine Modernization, Ministry of Education, Ningxia Engineering and Technology Research Center of Characteristic Chinese Medicine Modernization, College of Pharmacy, Ningxia Medical University, Yinchuan 750004, PR China.
| |
Collapse
|
10
|
Sudhindra P, Ajay Sharma S, Roy N, Moharana P, Paira P. Recent advances in cytotoxicity, cellular uptake and mechanism of action of ruthenium metallodrugs: A review. Polyhedron 2020. [DOI: 10.1016/j.poly.2020.114827] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
11
|
Sindhu M, Kalaivani P, Prabhakaran R. New organoruthenium metallates containing ferrocenecarboxalidine thiosemicarbazones and their nucleic acid/albumin binding and
in vitro
cytotoxicity. Appl Organomet Chem 2020. [DOI: 10.1002/aoc.5944] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Mathiyazhagan Sindhu
- Department of Chemistry, Nirmala College for Women Bharathiar University Coimbatore 641 018 India
| | - Palaniappan Kalaivani
- Department of Chemistry, Nirmala College for Women Bharathiar University Coimbatore 641 018 India
| | | |
Collapse
|
12
|
Basu U, Roy M, Chakravarty AR. Recent advances in the chemistry of iron-based chemotherapeutic agents. Coord Chem Rev 2020. [DOI: 10.1016/j.ccr.2020.213339] [Citation(s) in RCA: 38] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
13
|
Low-dimensional compounds containing bioactive ligands. Part XIII: Square planar anti-cancer Pd(II) complexes with halogenderivatives of 8-quinolinol and dimethylamine. Polyhedron 2020. [DOI: 10.1016/j.poly.2020.114535] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
14
|
Mandal P, Sonkar C, Dhankhar SS, Nagaraja C, Mukhopadhyay S. Ruthenium(II)-arene complexes containing ferrocenamide ligands: Synthesis, characterisation and antiproliferative activity against cancer cell lines. J Organomet Chem 2020. [DOI: 10.1016/j.jorganchem.2020.121247] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
15
|
Gelle D, Lamač M, Mach K, Šimková L, Gyepes R, Sommerová L, Martišová A, Bartošík M, Vaculovič T, Kanický V, Hrstka R, Pinkas J. Enhanced Intracellular Accumulation and Cytotoxicity of Ferrocene‐Ruthenium Arene Conjugates. Chempluschem 2020. [DOI: 10.1002/cplu.202000022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Donát Gelle
- J. Heyrovský Institute of Physical ChemistryAcademy of Sciences of the Czech Republic v.v.i. Dolejškova 2155/3 182 23 Prague 8 Czech Republic
- Department of ChemistryFaculty of EducationJ. Selye University Bratislavská cesta 3322 945 01 Komárno Slovak Republic
| | - Martin Lamač
- J. Heyrovský Institute of Physical ChemistryAcademy of Sciences of the Czech Republic v.v.i. Dolejškova 2155/3 182 23 Prague 8 Czech Republic
| | - Karel Mach
- J. Heyrovský Institute of Physical ChemistryAcademy of Sciences of the Czech Republic v.v.i. Dolejškova 2155/3 182 23 Prague 8 Czech Republic
| | - Ludmila Šimková
- J. Heyrovský Institute of Physical ChemistryAcademy of Sciences of the Czech Republic v.v.i. Dolejškova 2155/3 182 23 Prague 8 Czech Republic
| | - Róbert Gyepes
- J. Heyrovský Institute of Physical ChemistryAcademy of Sciences of the Czech Republic v.v.i. Dolejškova 2155/3 182 23 Prague 8 Czech Republic
- Department of ChemistryFaculty of EducationJ. Selye University Bratislavská cesta 3322 945 01 Komárno Slovak Republic
| | - Lucia Sommerová
- Regional Centre for Applied Molecular OncologyMasaryk Memorial Cancer Institute Žlutý kopec 7 65653 Brno Czech Republic
| | - Andrea Martišová
- Regional Centre for Applied Molecular OncologyMasaryk Memorial Cancer Institute Žlutý kopec 7 65653 Brno Czech Republic
| | - Martin Bartošík
- Regional Centre for Applied Molecular OncologyMasaryk Memorial Cancer Institute Žlutý kopec 7 65653 Brno Czech Republic
| | - Tomáš Vaculovič
- Department of ChemistryFaculty of ScienceMasaryk University Kamenice 753/5 62500 Brno Czech Republic
| | - Viktor Kanický
- Department of ChemistryFaculty of ScienceMasaryk University Kamenice 753/5 62500 Brno Czech Republic
| | - Roman Hrstka
- Regional Centre for Applied Molecular OncologyMasaryk Memorial Cancer Institute Žlutý kopec 7 65653 Brno Czech Republic
| | - Jiří Pinkas
- J. Heyrovský Institute of Physical ChemistryAcademy of Sciences of the Czech Republic v.v.i. Dolejškova 2155/3 182 23 Prague 8 Czech Republic
| |
Collapse
|
16
|
Dinuclear ruthenium(II) polypyridyl complexes: Mechanistic study with biomolecules, DNA/BSA interactions and cytotoxic activity. Polyhedron 2020. [DOI: 10.1016/j.poly.2019.114334] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
17
|
Wang R, Chen H, Yan W, Zheng M, Zhang T, Zhang Y. Ferrocene-containing hybrids as potential anticancer agents: Current developments, mechanisms of action and structure-activity relationships. Eur J Med Chem 2020; 190:112109. [PMID: 32032851 DOI: 10.1016/j.ejmech.2020.112109] [Citation(s) in RCA: 97] [Impact Index Per Article: 24.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2020] [Revised: 01/29/2020] [Accepted: 01/29/2020] [Indexed: 12/11/2022]
Abstract
Cancer is one of the most fatal threatens to human health throughout the world. The major challenges in the control and eradication of cancers are the continuous emergency of drug-resistant cancer and the low specificity of anticancer agents, creating an urgent need to develop novel anticancer agents. Organometallic compounds especially ferrocene derivatives possess remarkable structural and mechanistic diversity, inherent stability towards air, heat and light, low toxicity, low cost, reversible redox, ligand exchange, and catalytic properties, making them promising drug candidates for cancer therapy. Ferrocifen, a ferrocene-phenol hybrid, has demonstrated promising anticancer properties on drug-resistant cancers. Currently, Ferrocifen is in pre-clinical trial against cancers. Obviously, ferrocene moiety is a useful template for the development of novel anticancer agents. This review will provide an overview of ferrocene-containing hybrids with potential application in the treatment of cancers covering articles published between 2010 and 2020. The mechanisms of action, the critical aspects of design and structure-activity relationships are also discussed.
Collapse
Affiliation(s)
- Ruo Wang
- College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350116, China.
| | - Huahong Chen
- College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350116, China
| | - Weitao Yan
- College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350116, China
| | - Mingwen Zheng
- College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350116, China
| | - Tesen Zhang
- College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350116, China
| | - Yaohuan Zhang
- College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350116, China
| |
Collapse
|
18
|
Kuchárová V, Kuchár J, Zaric M, Canovic P, Arsenijevic N, Volarevic V, Misirkic M, Trajkovic V, Radojević ID, Čomić LR, Matik M, Potočňák I. Low-dimensional compounds containing bioactive ligands. Part XI: Synthesis, structures, spectra, in vitro anti-tumor and antimicrobial activities of 3d metal complexes with 8-hydroxyquinoline-5-sulfonic acid. Inorganica Chim Acta 2019. [DOI: 10.1016/j.ica.2019.119062] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
19
|
Chemistry and reactivity of ruthenium(II) complexes: DNA/protein binding mode and anticancer activity are related to the complex structure. Coord Chem Rev 2019. [DOI: 10.1016/j.ccr.2019.07.008] [Citation(s) in RCA: 74] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
20
|
Ruthenium(II) Complexes as Potential Apoptosis Inducers in Cancer Therapy. SERBIAN JOURNAL OF EXPERIMENTAL AND CLINICAL RESEARCH 2019. [DOI: 10.2478/sjecr-2019-0016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Abstract
The compound cis-diamminedichloroplatinum(II) (cisplatin) is the most widely used anticancer drug, but due to its serious side effects (including gastrointestinal symptoms, renal tubular injury, neuromuscular complications, and ototoxicity), clinical applications of cisplatin are limited. Therefore, these limitations have provided an encouragement for further research into other transition metal complexes, with an aim to overcome the disadvantages related with cisplatin therapy. In the search for effective complexes that can be targeted against tumor cells, many research groups synthesized various ruthenium( II) complexes with different ligands. Also, newly synthesized ruthenium(II) complexes showed selective anticancer activity against different types of cancer cells. Activity of ruthenium(II) complexes in some cases was even higher than that of cisplatin against the same cells. Precise mechanism of action of ruthenium(II) complexes is not fully understood. The different examples mentioned in this review showed that ruthenium(II) complexes decreased viability of cancer cells by induction of apoptosis and/or by cell cycle arrest which implies their different mechanism of action against different types of cancer cells.
Collapse
|